Trial Profile
A phase I/II study of temsirolimus and sunitinib in subjects with advanced renal cell carcinoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 23 Oct 2007
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Temsirolimus (Primary)
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Wyeth
- 11 Oct 2007 Status changed to discontinued - a decision was made not to trial a lower dose.
- 17 Sep 2007 Status changed from in progress to completed.
- 18 Jan 2007 New trial record.